United States: Amygdala Neurosciences Acquires GS-6637 From Gilead Sciences
Last Updated: March 7 2017

On February 16, 2017, Amygdala Neurosciences Inc., a biopharmaceutical company focused on the development and commercialization of first-in-class drug candidates for addiction disorders, announced that it entered into an agreement with Gilead Sciences, Inc. for the acquisition of GS-6637. GS-6637 is a highly selective ALDH2 inhibitor with the potential to treat behavior and substance addictions based on a mechanism of action that prevents pathophysiologic dopamine surges and associated craving without changes to basal dopamine.

WilmerHale is serving as legal counsel to Gilead on this transaction, with Eric Hwang leading the team that includes John Lee and Cindy Moon.

Read the full press release.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By WilmerHale
By WilmerHale
By Alan Wilson, Jonathan Wolfman
By WilmerHale
By Anna Gaudoin
By Rachel Jacobson, Nathaniel Custer, Mark Hanin
By Leila Gaafar
By Paul M. Architzel, Anjan Sahni, Matthew Beville, Daniel Martin
By Glenn Luinenburg
By Rachel Jacobson, Andrew L. Spielman, Sarah Judkins
Tools
Print
Font Size:
Translation
Channels